Skip to main content
. 2021 Aug 25;3(1):vdab118. doi: 10.1093/noajnl/vdab118

Table 3.

Assessment iRANO Response

iRANO 12 Months: n (%) 18 Months: n (%) 24 Months: n (%)
Complete response 4 (13.3) 5 (16.7) 2 (6.7)
Partial response 2 (6.7) 0 (0) 0 (0)
Stable disease 3 (10.0) 0 (0) 0 (0)
Disease progression 19 (63.3) 23 (76.7) 26 (86.7)